Table 2. Cost assumptions.
| AMD therapy |
Year 1 |
Years 2–3 |
||||
|---|---|---|---|---|---|---|
| Baseline | Low | High | Baseline | Low | High | |
| Anti-VEGF Injections | ||||||
| Attendance cost per injectiona | £500 | £400 | £600 | £500 | £400 | £600 |
| Attendance cost per follow-up visita | £65 | £52 | £78 | £65 | £52 | £78 |
| Cost of ranibizumab per injectionb | £913 | £913 | £913 | £913 | £913 | £913 |
| Cost of bevacizumab per injectionc | £75 | £55 | £107 | £75 | £55 | £107 |
| Allowance for possible future cataract procedurea,d | £13 | £10 | £16 | £12 | £9 | £14 |
| EMB | ||||||
| Cost of vitrectomy per patienta | £1124 | £900 | £1349 | £0 | £0 | £0 |
| Cost of radiotherapy physics support per patienta | £200 | £160 | £240 | £0 | £0 | £0 |
| Cost of RDM per patiente | £125 | £100 | £150 | £0 | £0 | £0 |
| Cost of DDM per patientf | £4200 | £4200 | £4200 | £0 | £0 | £0 |
| Allowance for possible future cataract procedurea,d | £309 | £247 | £371 | £26 | £21 | £31 |
Abbreviations: DDM, disposable delivery module; EMB, epimacular brachytherapy; RDM, reusable delivery module; VEGF, vascular endothelial growth factor.
Low/high values are ±20% compared with the baseline value.
Cited as book price for Lucentis plus VAT (value-added tax; 20%).
Low/high values are based on the lower and higher values (plus VAT) quoted for providing bevacizumab in a pre-filled 1.25 mg syringe, from three UK compounding pharmacies.
The allowance for cataract surgery is based on the cost of surgery and the percentage of phakic patients predicted to develop cataract over the 3-year projection.2, 3 The details of the assumptions are provided in the text.
Baseline value assumes that a single RDM unit (rental cost of £250 per month) is used for 24 patients over 1 year. Low/high values are ±20% compared with the baseline value.
Cost of DDM is £3500 (plus VAT) and is set by the manufacturer, and is assumed not to vary.